Explore Your Local Site

Looks like you've landed on our   site. Let's take you home:    

Please note that the content and products on the    site might not be available in your region.

 

  Homepage
Continue on the current website:  

 

VIDA Insights

VIDA Insights is a comprehensive lung intelligence solution, empowering providers with quantitative data and impactful visualizations.

Inquire Now

VIDA
  • CT
  • Pulmonary
  • Thoracic

Empowering Providers with Lung Intelligence

VIDA Insights automatic analysis is an Al-powered analysis of an inspiratory chest CT scan, providing a flag of lung density abnormalities that may be indicative of emphysema (COPD) or interstitial lung abnormalities (IL As).

    1. Nam liber tempor cum soluta nobis eleifend option congue nihil imperdiet doming

    2. Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Magna aliquam erat volutpat tempo molestie vesse

    1. Nam liber tempor cum soluta nobis eleifend option congue nihil imperdiet doming

    2. Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Magna aliquam erat volutpat tempo molestie vesse

     

      Topographic MPR (tMPR)

      The tMPR is a patented technique to quickly review the majority of airways (80-95%) in a patient in three images: 1) coronal, 2) sagittal right, and 3) sagittal left, all without compromising context and resolution. Unlike traditional curved multiplanar reformations (MPR) and minimum intensity projections (MinlP), tMPR maximizes the number of airways in a single view while maintaining orientation, branching complexity and resolution. Traditional rendering techniques cannot offer all these features in a single view.

      Lung Density & tMPR - Density & Volumetric Analysis

      Density & Volumetric Analysis There are three density bands displayed (low, normal, and high) that visually demonstrate the density distribution along with providing a quantified density analysis. % Low Density defined as ≤-950 HUas a surrogate for emphysema, flagged when ≥ 5%.% Normal Density defined as between >-950 HU and <-700 HU as a surrogate for normal lung tissue that is unremarkable.% High Density defined as -700 HU to -250 HU as a surrogate for interstitial lung abnormalities (e.g., ground glass opacities, reticulations), flagged when ≥ 10%.These visuals show the density percentages for each lung region along with color coding for the low and high densities. Low- and high­ density percentages will only appear if the percentage is above the physiologically significant threshold as indicated above. The percentages of normal lung density will always be displayed. The coloring used to flag physiologically significant low- or high-density uses a continuous gradient, meaning that as the low- or high­ density % increases, the coloring displayed will gradually get darker showing relative difference quickly and over time.

      Texture & Subpleura Views

      The texture analysis section is automatically generated when Insights has flagged areas of High Density in either the lung or lobe at the clinically significant threshold (≥10% High Density) relating to interstitial lung abnormalities. This section will be suppressed when the High Density does not meet this threshold, when contrast media is present, or in the instance of an algorithm failure. Texture includes the features of Ground Glass/Reticulations, Consolidation and Honeycombing. These features are classified and quantified by percentage and liters of total area affected. A lung schematic is provided to assess distribution of texture in each lung, lobe and core/peel region including peripheral, central, or diffuse (central and peripheral).

      Automatic Analysis

      VIDA Insights automatic analysis is an Al-powered analysis of an inspiratory chest CT scan, providing a quick flag of lung density abnormalities that may be indicative of emphysema (COPD) or interstitial lung abnormalities (IL As). The analysis includes enhanced airway visualizations (topographic MPRs (tMPR)) to increase the quality, precision, and efficiency in reviewing and analyzing respiratory CT abnormalities.

      References

      1. Cosgrove et al, Barriers to timely diagnosis interstitial lung disease, BMC Pulmonary Medicine, 2018
      2. FDA Summary K200990
      3. LL-60010 VIDA Insights IFU platforms V3.3 September 2021
      4. https://blog.vidalung.ai/osf-healthcare-partnership
      Request a demo

      See Ahead for Yourself

      Inquire now